Amgen Inc (AMGN)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ
Market Cap: $250.07B
Last updated: Nov 17, 2026 at 4:44 PM ET
Amgen Inc (AMGN) Statistics
Amgen (AMGN) has a market cap of $250.07B and an enterprise value of $290.89B. Its trailing P/E of 19.8x is above its 10-year median of 14.3x.
Total Valuation
Enterprise value is 16.32% above the market cap, as debt exceeds cash.
| Market Cap | $250.07B |
|---|---|
| Enterprise Value | $290.89B |
| Latest price (Nov 17, 2026) | $457.93 |
Key Dates
The next earnings report is expected on Feb 1, 2027, covering the quarter ending Dec 31, 2026. The next ex-dividend date is Nov 20, 2026.
| Next Earnings Date | Feb 1, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 3, 2026 |
| Next Ex-Dividend Date | Nov 20, 2026 |
| Next Payment Date | Dec 11, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 6.4x and 17.3x. Its year-end P/E ranged from 12.6x to 16.3x from 2016 to 2025.
| P/E Ratio | 19.8x |
|---|---|
| Forward P/E | 19.1x |
| P/S Ratio | 6.4x |
| Forward P/S | 6.3x |
| P/B Ratio | 17.3x |
| P/FCF Ratio | 25.9x |
| P/OCF Ratio | 20.8x |
| PEG Ratio | 3.0 |
Enterprise Valuation
Counting debt and cash, the company is valued at 15.9x EBITDA and 30.1x free cash flow.
| EV / Earnings | 31.0x |
|---|---|
| EV / Sales | 7.5x |
| EV / EBITDA | 15.9x |
| EV / EBIT | 21.3x |
| EV / FCF | 30.1x |
Price Statistics
The stock is up 37.88% over 52 weeks and trades 7.22% above its 50-day average.
| Beta (1Y) | 0.50 |
|---|---|
| 52-Week Change | +37.88% |
| 1-Month Change | +7.76% |
| 3-Month Change | +4.11% |
| 6-Month Change | +39.25% |
| 5-Year Change | +125.16% |
| 10-Year Change | +230.13% |
| Total Return (1Y) | +40.88% |
| Total Return (3Y CAGR) | +22.15% |
| Total Return (5Y CAGR) | +20.42% |
| Return vs SPY (1Y) | +23.42% |
| Max Drawdown (1Y) | -17.04% |
| Max Drawdown (3Y) | -22.73% |
| Sharpe Ratio (1Y) | 1.05 |
| Correlation with SPY (1Y) | 0.24 |
| 50-Day Average | $427.10 |
| 200-Day Average | $380.10 |
| 52-Week Range | $306.13 to $483.99 |
| RSI (14 Days) | 55.3 |
| Average Volume (20 Days) | 2.65M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.48x current liabilities, and total debt is 3.76x shareholder equity.
| Current Ratio | 1.48x |
|---|---|
| Quick Ratio | 1.20x |
| Debt / Equity | 3.76x |
| Debt / EBITDA | 2.97x |
| Debt / FCF | 5.64x |
| Interest Coverage | 5.19x |
Returns and Efficiency
Return on invested capital is 17.01% over the last 12 months, against a 5-year average of 15.00%.
| Return on Equity (ROE) | 65.43% |
|---|---|
| Return on Assets (ROA) | 9.78% |
| Return on Invested Capital (ROIC) | 17.01% |
| Return on Capital Employed (ROCE) | 18.80% |
| ROE (5Y Average) | 106.67% |
| ROA (5Y Average) | 7.92% |
| ROIC (5Y Average) | 15.00% |
| Asset Turnover | 0.42x |
| Inventory Turnover | 1.80x |
| Receivables Turnover | 3.78x |
| Cash Conversion Cycle | 206 days |
Taxes
Income tax took 15.03% of pretax income over the last 12 months.
| Income Tax (TTM) | $1.66B |
|---|---|
| Effective Tax Rate | 15.03% |
Scores
AMGN has an Altman Z-Score of 2.55, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 2.55 |
|---|---|
| Altman Z Zone | Grey |
| Piotroski F-Score | 7 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $38.90B over the last 12 months is up 8.15% from the 12 months before.
| Revenue | $38.90B |
|---|---|
| Revenue Growth (YoY) | +8.15% |
| Gross Profit | $27.58B |
| Operating Income | $12.61B |
| Pretax Income | $11.05B |
| Net Income | $9.39B |
| EBITDA | $18.17B |
| EBIT | $13.69B |
| Reported EPS (TTM) | $23.18 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 14.94% of the $96.05B in total assets.
| Cash and Equivalents | $13.19B |
|---|---|
| Total Debt | $54.01B |
| Net Debt | $40.82B |
| Net Debt Per Share | $75.45 |
| Working Capital | $11.13B |
| Shareholder Equity | $14.35B |
| Book Value Per Share | $26.53 |
| Tangible Book Value | -$23.85B |
| Total Assets | $96.05B |
| Total Liabilities | $81.70B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $2.45B of capital spending, operating cash flow left $9.58B of free cash flow.
| Operating Cash Flow | $12.04B |
|---|---|
| Capital Expenditures | $2.45B |
| Free Cash Flow | $9.58B |
| FCF Per Share | $17.72 |
| Depreciation and Amortization | $4.48B |
| Dividends Paid | $5.37B |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 32.41%, against a 5-year average of 28.04%.
| Gross Margin | 70.90% |
|---|---|
| Operating Margin | 32.41% |
| Pretax Margin | 28.41% |
| Net Margin | 24.14% |
| EBITDA Margin | 46.71% |
| EBIT Margin | 35.18% |
| FCF Margin | 24.63% |
| Gross Margin (5Y Average) | 69.92% |
| Operating Margin (5Y Average) | 28.04% |
| Net Margin (5Y Average) | 20.92% |
Growth
Revenue grew 11.77% a year over 3 years, and EPS 7.29% a year.
| Revenue Growth (3Y CAGR) | +11.77% |
|---|---|
| Revenue Growth (5Y CAGR) | +7.65% |
| EPS Growth (3Y CAGR) | +7.29% |
| EPS Growth (5Y CAGR) | +5.65% |
| FCF Growth (3Y CAGR) | -2.67% |
| FCF Growth (5Y CAGR) | -3.91% |
| Operating Income Growth (3Y CAGR) | -1.72% |
| Book Value Per Share Growth (2Y CAGR) | +17.54% |
Dividends and Yields
AMGN pays out 44.68% of earnings as dividends.
| Dividend Per Share (Annual) | $10.08 |
|---|---|
| Dividend Yield | 2.20% |
| Payment Schedule | Quarterly |
| Dividend Growth (3Y CAGR) | +7.05% |
| Dividend Growth (5Y CAGR) | +8.27% |
| Payout Ratio | 44.68% |
| FCF Payout Ratio | 56.01% |
| Earnings Yield | 5.05% |
| FCF Yield | 3.87% |
| Shareholder Yield | 2.17% |
Stock Splits
The last split was a 2-for-1 forward split on Nov 22, 1999.
| Last Split Date | Nov 22, 1999 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 2:1 |
Peer Position
Against 9 similar companies, AMGN has the 6th highest P/E.
P/E RatioPeer median 21.3x
P/S RatioPeer median 4.1x
ROICPeer median 12.84%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +5.31%
Dividend YieldPeer median 2.69%
| P/E Ratio | 19.8x vs 21.3x median |
|---|---|
| P/S Ratio | 6.4x vs 4.1x median |
| ROIC | 17.01% vs 12.84% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +8.15% vs +5.31% median |
| Dividend Yield | 2.20% vs 2.69% median |
Analyst Forecast
Consensus estimates put revenue growth at 5.99% and EPS growth at 7.08% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +5.99% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +7.08% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About AMGN
What is AMGN's market cap?
Amgen has a market cap of $250.07B. Its enterprise value, which adds debt and subtracts cash, is $290.89B.
What is AMGN's P/E ratio?
Amgen has a trailing P/E ratio of 19.8x and a forward P/E of 19.1x.
How many shares of AMGN are outstanding?
Amgen has 541.00M shares outstanding. The count is up 0.56% from a year earlier.
Does AMGN pay a dividend?
Yes. Amgen pays $10.08 a share a year, a dividend yield of 2.20%.
How much debt does AMGN have?
Amgen has $54.01B of total debt and $13.19B of cash and equivalents, a net debt position of $40.82B.
AMGN pages: Overview, Dividends, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts